Sharing personal information brings people closer together. But how do you know when you’ve gone too far—or when someone else has ulterior motives?
Verified by Psychology Today
A resource for patients and families
Charles Zorumski M.D., Eugene Rubin M.D., Ph.D.
Two recently approved antidepressant medications may represent the beginning of a second revolution in psychopharmacology.
An important study indicates that alcohol and drug use are major contributors to the overall burden of disease worldwide.
A recent study provides evidence that anorexia nervosa is both a psychiatric and metabolic disorder.
Early diagnosis of bipolar disorder is important so that appropriate treatments can be initiated. However, diagnosis can be challenging. Why?
Suicide rates in the U.S. have increased about 35 percent since the year 2000. Death rates from unintentional overdoses, however, have increased 450 percent over the same period.
When adults report being maltreated as children, are their reports always accurate? When children experience maltreatment, do they recall it later as adults?
A study of health claims data demonstrates that the use of medications to treat ADHD is associated with a decrease in later substance use-related events.
Substantial progress is being made to develop blood tests that can detect early stages of brain degeneration.
Should physician-assisted death be allowed for psychiatrically ill patients who find the suffering from their disorders unbearable?
A 2018 study indicates that differences in cognitive function can be detected at a very early age in individuals who are later diagnosed with schizophrenia.
A recently approved drug to treat seizures may also have clinically significant antidepressant properties.
Recent genetic data support the possibility of a common factor underlying multiple psychiatric disorders.
Persons with ALS often demonstrate behavioral changes. Research indicates that their family members may have an increased risk of certain psychiatric disorders.
Primary care providers will become more involved in screening for a variety of psychiatric conditions.
Traumatic brain injuries are associated with increased rates of suicide even in those without pre-existing psychiatric conditions.
A specific parent-child therapy substantially decreases depressive symptoms in very young children and offers hope of diminishing longer-term consequences.
In a study, two 8-hour MDMA-assisted psychotherapy sessions, together with extensive follow-up, led to substantial improvement in PTSD symptoms.
Several mechanistically different treatments have been proposed for PTSD. A type of mindfulness-based treatment can now be added to this list.
Research indicates that 10 percent of adults experienced depression during the previous year. About 50 percent of those had received some sort of treatment.
Psychedelics may have therapeutic value for people with certain psychiatric disorders. But are the individual and societal risks worth it?
There are drugs that rapidly lead to increased connections between nerve cells and have therapeutic potential for treating psychiatric illnesses.
Marijuana contains two chemicals that have very different effects.
Medications can help children and adolescents with depression and anxiety, but they can have significant side effects. It may be better to try non-pharmacologic approaches first.
A study that evaluated thousands of participants over several decades concluded that depressions occurring during middle age do not lead to dementia.
Psychotic symptoms increase in frequency and severity as Parkinson’s disease progresses. Non-pharmacologic and pharmacologic treatments can be helpful.
Although ketamine may decrease suicidal ideations in persons with depression, little is known about its use in other conditions associated with suicidal thoughts.
The patterns of functional connections between the amygdala and other brain regions may be useful in predicting early psychiatric symptoms in children.
A prospective epidemiological study indicates that marijuana use is associated with nonmedical use of prescription opiates three years later.
Forty-seven percent of individuals who experience acute psychotic symptoms following marijuana use later develop schizophrenia or bipolar disorder. Half do so within 3 to 4 years.
A technique to selectively stimulate specific brain regions without the need for surgery has been developed recently. Such technology has tremendous therapeutic potential.
Charles F. Zorumski, MD, is Samuel B. Guze Professor and Head of Psychiatry at Washington University in St. Louis - School of Medicine.
Eugene Rubin, M.D., Ph.D., is Professor and Vice-Chair for Education in the Department of Psychiatry at Washington University in St. Louis - School of Medicine.